Is retatrutide illegal in the US?

It is not scheduled under the Controlled Substances Act. It is unapproved, meaning the FDA has authorised no product containing it, and it may not be marketed for human use.

When could retatrutide become legal to prescribe?

Not before approval. Lilly has signalled an FDA filing for the first quarter of 2027, following completion of the TRIUMPH programme. Review typically takes months beyond a filing.

Retatrutide Research

Is Retatrutide Legal?

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-313 cited sources

Retatrutide is not a controlled substance in the UK or the US. It is an unapproved investigational compound, which is a different legal category: it holds no marketing authorisation, so it cannot lawfully be supplied or promoted for human use, but possessing it is not itself an offence the way a controlled drug would be.

Key facts

UK controlled drug status: Not scheduled
UK marketing authorisation: None
US scheduling: Not scheduled
US approval: None; filing signalled for 2027
Lawful supply route: Clinical trial, or research use

Unapproved is not the same as illegal

These are two different regimes and conflating them produces confident wrong answers in both directions. Controlled drug legislation — the Misuse of Drugs Act in the UK, the Controlled Substances Act in the US — schedules substances by abuse potential. Retatrutide appears in neither. Medicines legislation is separate, and governs whether something may be sold or supplied as a medicine. Retatrutide has no authorisation under that regime anywhere in the world.

What that means for supply

Supplying or advertising an unlicensed medicine for human use is an offence under the Human Medicines Regulations 2012 in the UK, irrespective of scheduling. That is why research material is supplied on research-use terms and why no legitimate supplier will describe it as suitable for administration to a person.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why it is not approved yet

Approval follows a completed Phase 3 programme and a regulatory filing. Retatrutide's TRIUMPH trials are ongoing, with TRIUMPH-5 completing in November 2026, and Lilly has signalled an FDA submission for the first quarter of 2027. Until a regulator has reviewed that dossier, there is nothing to approve.

Sport and employment rules are separate again

A substance can be lawful to possess and still prohibited under anti-doping rules, which operate independently of both medicines and controlled drug law. Athletes subject to WADA-compliant testing should treat regulatory status and prohibited-list status as unrelated questions.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals — research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is retatrutide legal in the UK?: It is not a controlled substance under the Misuse of Drugs Act. It also holds no UK marketing authorisation, so it cannot lawfully be supplied or advertised for human use under the Human Medicines Regulations 2012.
Is retatrutide illegal in the US?: It is not scheduled under the Controlled Substances Act. It is unapproved, meaning the FDA has authorised no product containing it, and it may not be marketed for human use.
When could retatrutide become legal to prescribe?: Not before approval. Lilly has signalled an FDA filing for the first quarter of 2027, following completion of the TRIUMPH programme. Review typically takes months beyond a filing.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum